KOREA WHO

Lee Jong-seo is the CEO of AbClon.

He was born on March 15, 1963, in Seoul.

Lee earned his bachelor's degree in biology from Sogang University and a master's degree in biochemistry from Yonsei University Graduate School. He later received a doctorate in pathology from Kyoto University Graduate School of Medicine in Japan.

He began his career as a researcher at the Chong Kun Dang Research Institute and continued his work at Harvard Medical School in the United States.

After returning to Korea, he served as Head of the Bio Business Division at LabFrontier, a biotech company specializing in antibody-based new drug development. In 2007, he was recruited as CEO of AB Frontier, an antibody development company. The following year, he was appointed CEO of Youngin Frontier (now A-Frontier), also focused on antibodies.

In 2010, Lee co-founded AbClon with a group of Korean and Swedish scientists, transitioning from a professional manager to an owner-manager.

He aims to establish AbClon as a global biotech company that develops antibody-based pharmaceuticals capable of drawing global attention from the medical community and transferring its technologies to partners worldwide.

#AbClon #LeeJongseo #biotech #antibody #pharmaceuticals #CEO #HarvardMedicalSchool #KyotoUniversity #KoreaBiotech #globalbio